Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis.

导出 OA

翻译打印收藏纠错

第一作者： Yueying,Chen

第一单位： Department of Respiratory and Critical Care Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.

作者： Yueying,Chen ^[1] ; Hedong,Han ^[1] ; Jing,Cheng ^[1] ; Qinpei,Cheng ^[1] ; Suhua,Zhu ^[1] ; Ping,Zhan ^[1] ; Hongbing,Liu ^[1] ; Yong,Song ^[1] ; Tangfeng,Lv ^[2]

作者单位： Department of Respiratory and Critical Care Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. ^[1] Department of Respiratory and Critical Care Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. bairoushui@163.com. ^[2]

关键词 Immunotherapy PD-1/PD-L1 inhibitor Solid tumor Therapy combination

主题词人类(Humans);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);免疫疗法(Immunotherapy);肿瘤(Neoplasms);随机对照试验(主题)(Randomized Controlled Trials as Topic)

DOI 10.1007/s00262-024-03734-1

PMID 38834888

发布时间 2024-10-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交